MedTrace Logo

Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain

NCT03947749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2023-08-14

No results posted yet for this study

Summary

Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.

Conditions

  • Pain, Chronic
  • Prescription Drug Abuse (Not Dependent)

Sponsors & Collaborators

  • Florida Medical Malpractice Joint Underwriting Association

    collaborator UNKNOWN

  • University of Florida

    lead OTHER

Principal Investigators

  • Sophia Sheikh, MD · University of Florida

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-25
Primary Completion
2023-04-05
Completion
2023-04-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947749 on ClinicalTrials.gov